Skip to main content
Find more clinical trials

Imaging Neurodegeneration With [18F]3F4AP

Start: January 25, 2021
End: December 1, 2025
Enrollment: 66

What Is This Study About?

This Phase 1 study will evaluate the safety and feasibility of using [18F]3F4AP as a positron emission tomography (PET) tracer to detect the breakdown of neurons, called neurodegeneration, in the brains of people with mild cognitive impairment (MCI), Alzheimer's disease, or traumatic brain injury (TBI). All participants will receive an injection of [18F]3F4AP followed by a PET scan and MRI of the brain. Participants with Alzheimer's, MCI, or TBI will also undergo neuropsychological testing. Researchers will assess the distribution of the tracer in the body using a CT scan and monitor all participants for any adverse events for five years. The results of this study may be used to develop new tools to diagnose neurodegenerative diseases and conditions.

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: 90 Years

Must have:

  • Adult who is one of the following:
    • Healthy volunteer
    • Person with MCI
    • Person with TBI
    • Person with Alzheimer's disease (60 to 90 years of age)

Must NOT have:

  • Any condition or device that could make getting an MRI, computed tomography (CT), or PET scan unsafe (e.g., claustrophobia, morbid obesity, metal implants, heart pacemaker, etc.)
  • Pregnant or breastfeeding
  • Women of childbearing age must have a negative pregnancy test result the day of the PET or CT scan 

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Study Contact
Georges El Fakhri, PhD

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Massachusetts General Hospital
Boston, MA 02114
Marina Macdonald-Soccorso, BS

Who Sponsors This Study?

Lead: Massachusetts General Hospital

Source: ID: NCT04710550